Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection
- PMID: 4550416
- DOI: 10.1093/infdis/125.1.12
Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection
Similar articles
-
Immunity in shigellosis. I. Response of man to attenuated strains of Shigella.J Infect Dis. 1972 Jan;125(1):5-11. doi: 10.1093/infdis/125.1.5. J Infect Dis. 1972. PMID: 4550417 No abstract available.
-
Immunity against dysentery after enteral immunization with live vaccine.Acta Microbiol Acad Sci Hung. 1974;21(1-2):71-4. Acta Microbiol Acad Sci Hung. 1974. PMID: 4613140 No abstract available.
-
Live oral Shigella vaccine: vaccination schedule and the effect of booster dose.Acta Microbiol Acad Sci Hung. 1974;21(1-2):109-14. Acta Microbiol Acad Sci Hung. 1974. PMID: 4613128 No abstract available.
-
Live attenuated Shigella flexneri mutants as vaccine candidates against shigellosis and vectors for antigen delivery.Biologicals. 1995 Jun;23(2):125-34. doi: 10.1006/biol.1995.0023. Biologicals. 1995. PMID: 7546655 Review.
-
Oral shigella vaccines.Curr Top Microbiol Immunol. 1989;146:205-11. doi: 10.1007/978-3-642-74529-4_22. Curr Top Microbiol Immunol. 1989. PMID: 2659269 Review. No abstract available.
Cited by
-
Comparative immunogenicity of heat-killed and living oral Salmonella vaccines.Infect Immun. 1972 Oct;6(4):451-8. doi: 10.1128/iai.6.4.451-458.1972. Infect Immun. 1972. PMID: 4564282 Free PMC article.
-
Homologous and heterologous re-challenge with Salmonella Typhi and Salmonella Paratyphi A in a randomised controlled human infection model.PLoS Negl Trop Dis. 2020 Oct 20;14(10):e0008783. doi: 10.1371/journal.pntd.0008783. eCollection 2020 Oct. PLoS Negl Trop Dis. 2020. PMID: 33079959 Free PMC article. Clinical Trial.
-
Detection of a leukocytic endogenous mediator-like mediator of serum amino acid and zinc depression during various infectious illnesses.Infect Immun. 1975 Apr;11(4):873-5. doi: 10.1128/iai.11.4.873-875.1975. Infect Immun. 1975. PMID: 1091555 Free PMC article.
-
Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans.Infect Immun. 2000 Mar;68(3):1034-9. doi: 10.1128/IAI.68.3.1034-1039.2000. Infect Immun. 2000. PMID: 10678904 Free PMC article.
-
Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG.Infect Immun. 1996 Nov;64(11):4542-8. doi: 10.1128/iai.64.11.4542-4548.1996. Infect Immun. 1996. PMID: 8890204 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical